Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on PolarityTE Inc (PTE) today. The company’s shares opened today at $15.25, close to its 52-week low of $11.54.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 16.2% and a 56.8% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PolarityTE Inc with a $43.75 average price target, representing a 186.9% upside. In a report issued on March 10, Piper Jaffray also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on PolarityTE Inc’s latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $22.49 million. In comparison, last year the company had a GAAP net loss of $14.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant.
